share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

SEC ·  Sep 7 05:00
Summary by Futu AI
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 40,000 shares of the company's Class A Common Stock on September 4 and 5, 2024. The transactions were executed at prices ranging from $6.04 to $6.14 per share, resulting in a total market value of $243,600. Following the sales, Gibson directly holds 762,656 shares of Recursion Pharmaceuticals.
Recursion Pharmaceuticals CEO Christopher Gibson completed a sale of 40,000 shares of the company's Class A Common Stock on September 4 and 5, 2024. The transactions were executed at prices ranging from $6.04 to $6.14 per share, resulting in a total market value of $243,600. Following the sales, Gibson directly holds 762,656 shares of Recursion Pharmaceuticals.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.